Nuclear receptors as regulators of tissue responses and potential targets for anti-fibrotic therapies

• Applicant: Professor Dr. Jörg Hans Wilhelm Distler
• Subject Area: Rheumatology
• Term: from 2014 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 258918299

• Final Report Year: 2020

Final Report Abstract

No abstract available

Publications

• Hippocampal structure and function are maintained despite severe innate peripheral inflammation. Brain, Behavior, and Immunity, Vol. 49. 2015, pp. 156-170.
  Süß P., Kalinichenko L., Baum W., Reichel M., Kornhuber J., Loskarn S., Ettle B., Distler J.H., Schett G., Winkler J., Müller C.P., Schlachetzki J.C.
  (See online at https://doi.org/10.1016/j.bbi.2015.05.011)
• Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis. Clinical Chemistry and Laboratory Medicine (CCLM), Band 53. 2015, Heft 11, S. 1799-1805.
  Legány N., Toldi G., Distler J.H., Beyer C., Szalay B., Kovács L., Vásárhelyi B., Balog A.
  (See online at https://doi.org/10.1515/cclm-2015-0079)
• Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis. Annals of the Rheumatic Diseases, Vol. 75. 2016, Issue 11, pp. 2037-2044.
  Lin N.Y., Distler A., Beyer C., Philipi-Schöbinger A., Breda S., Dees C., Stock M., Tomcik M., Niemeier A., Dell'Accio F., Gelse K., Mattson M.P., Schett G., Distler J.H.
  (See online at https://doi.org/10.1136/annrheumdis-2015-208420)
• N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. International Journal of Cardiology, Vol. 223. 2016, pp. 385-389.
  Allanore Y-, Komocsi A-, Vettori S-, Hachulla E-, Hunzelmann N-, Distler J-, Avouac J-, Gobeaux C-, Launay D-, Czirjak L-, Kahan A-, Meune C.
  (See online at https://doi.org/10.1016/j.ijcard.2016.08.246)
• Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clinical and Experimental Rheumatology, Vol. 35. 2017, Suppl. 106, pp. S75-S81.
  Distler O., Brown K.K., Distler J.H.W., Assassi S., Maher T.M., Cottin V, Varga J., Coeck C., Gahlemann M., Sauter W., Schmidt H., Highland K.B., SENSCIS™ trial investigators
  
• Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis. Experimental Dermatology, Vol.26. 2017, Issue 1, pp. 73-81.
  Dosoki H., Stegemann A., Taha M., Schnittler H., Luger T.A., Schröder K., Distler J.H., Kerkhoff C., Böhm M.
  (See online at https://doi.org/10.1111/exd.13180)
• Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, Vol. 9. 2018: 989.
  Biermann M.H.C., Boeltz S., Pieterse E., Knopf J., Rech J., Bilyy R., van der Vlag J., Tincani A., Distler J.H.W., Krönke G., Schett G.A., Herrmann M., Muñoz L.E.
  (See online at https://doi.org/10.3389/fimmu.2018.00989)
• NR4A1 regulates motility of osteoclast precursors and serves as target for the modulation of systemic bone turnover. Journal of Bone and Mineral Research, Vol. 33. 2018, Issue 11 pp. 2035-2047.
  Scholtysek C., Ipseiz N., Böhm C., Krishnacoumar B., Stenzel M., Czerwinski T., Weidner D., Klej A., Stoll C., Distler J., et al.
  (See online at https://doi.org/10.1002/jbmr.3533)
• Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. Journal of Rheumatology, Vol. 45. 2018, Issue 3, pp. 405-410.
  Hsu V.M., Denton C.P., Domsic R.T., Furst D.E., Rischmueller M., Stanislav M., Steen V.D., Distler J.H.W., Korish S., Cooper A., Choi S., Schafer P.H., Horan G., Hough D.R.
  (See online at https://doi.org/10.3899/jrheum.161040)
• GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications, Vol. 10. 2019, Issue 1, Article number: 4955.
  López-Isac E., Acosta-Herrera M., Distler J.H.W., Martin J., et al.
  (See online at https://doi.org/10.1038/s41467-019-12760-y)
• Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs. Annals of the Rheumatic Diseases, Vol. 78. 2019, Issue 12, pp. 1686-1692.
  Matei A.E., Chen C.W., Kiesewetter L., Györfi A.H., Li Y.N., Distler J.H.W., et al.
  (See online at https://doi.org/10.1136/annrheumdis-2019-216108)